All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2023-04-14T13:02:22.000Z

ASAP: Conditioning vs induction + allo-HSCT in R/R AML

Apr 14, 2023
Share:
Learning objective: After reading this visual abstract, learners will be able to cite a new development in the treatment of R/R AML.

Bookmark this article

The AML Hub is pleased to present a visual abstract summarizing key results from the non-inferiority phase III ASAP trial comparing sequential conditioning prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT) versus salvage chemotherapy followed by allo-HSCT in patients with poor response to first induction or relapsed/refractory acute myeloid leukemia.

The findings from the ASAP trial were recently presented by Schetelig1 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition. The findings suggest that watchful waiting along with sequential conditioning prior to allo-HSCT may improve outcomes in patients with relapsed/refractory acute myeloid leukemia and with a readily available stem cell donor.


Visual Abstract

To download this visual abstract, click below.

Download here

  1. Schetelig J. In patients with relapsed/refractory AML sequential conditioning and immediate allogeneic stem cell transplantation (allo-HCT) results in similar overall and leukemia-free survival compared to intensive remission induction chemotherapy followed by allo-HCT: Results from the randomized phase III ASAP trial. Plenary scientific session #4. 64th American Society of Hematology Annual Meeting and Exposition; Dec 11, 2022; New Orleans, US.

Your opinion matters

Do you intend to implement next generation sequencing for measurable residual disease monitoring in AML patients?
0 votes - 6 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox